Abstract
BackgroundCabozantinib, a multiple receptor tyrosine kinase inhibitor, promotes an immune-permissive environment which might enhance activity of immune checkpoint inhibitors (ICI). COSMIC-021 (NCT03170960), a multicenter phase 1b study, is evaluating cabozantinib...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
